BRCA; Bayesian network meta-analysis; HER2-low; Immunotherapy; PARP inhibitors; PD-L1; Pembrolizumab; Sacituzumab govitecan; Therapeutic algorithm; Trastuzumab deruxtecan; Triple negative breast cancer; Bevacizumab; Poly(ADP-ribose) Polymerase Inhibitors; B7-H1 Antigen; Paclitaxel; Humans; Bevacizumab/therapeutic use; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use; Network Meta-Analysis; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Algorithms; Triple Negative Breast Neoplasms; Oncology; Radiology, Nuclear Medicine and Imaging; General Medicine
Abstract :
[en] Metastatic triple-negative breast cancer (mTNBC) is a poor prognostic disease with limited treatments and uncertain therapeutic algorithms. We performed a systematic review and multiple Bayesian network meta-analyses according to treatment line to establish an optimal therapeutic sequencing strategy for this lethal disease. We included 125 first-line trials (37,812 patients) and 33 s/further-lines trials (11,321 patients). The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall response rates (ORR), overall survival (OS) and safety, for first and further lines, separately. We also estimated separate treatment rankings for the first and subsequent lines according to each endpoint, based on (surface under the cumulative ranking curve) SUCRA values. No first-line treatment was associated with superior PFS and OS than paclitaxel ± bevacizumab. Platinum-based polychemotherapies were generally superior in terms of ORR, at the cost of higher toxicity.. PARP-inhibitors in germline-BRCA1/2-mutant patients, and immunotherapy + chemotherapy in PD-L1-positive mTNBC, performed similar to paclitaxel ± bevacizumab. In PD-L1-positive mTNBC, pembrolizumab + chemotherapy was better than atezolizumab + nab-paclitaxel in terms of OS according to SUCRA values. In second/further-lines, sacituzumab govitecan outperformed all other treatments on all endpoints, followed by PARP-inhibitors in germline-BRCA1/2-mutant tumors. Trastuzumab deruxtecan in HER2-low mTNBC performed similarly and was the best advanced-line treatment in terms of PFS and OS after sacituzumab govitecan, according to SUCRA values. Moreover, comparisons with sacituzumab govitecan, talazoparib and olaparib were not statistically significant. The most effective alternatives or candidates for subsequent lines were represented by nab-paclitaxel (in ORR), capecitabine (in PFS) and eribulin (in PFS and OS).
Disciplines :
Oncology
Author, co-author :
Schettini, Francesco; Translational Genomics and Targeted Therapies in Solid Tumors, 08036 Barcelona, Spain, Department of Medical Oncology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain, Department of Medicine, University of Barcelona, 08036 Barcelona, Spain. Electronic address: schettini@clinic.cat
Venturini, Sergio; Department of Economic and Social Sciences, Catholic University of Sacred Heart - Cremona Campus, 26100 Cremona, Italy. Electronic address: sergio.venturini@unicatt.it
Giuliano, Mario; Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy. Electronic address: m.giuliano@unina.it
Lambertini, Matteo; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, 16132 Genova, Italy, Department of Medical Oncology, U.O.C Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy. Electronic address: matteo.lambertini@unige.it
Pinato, David J; Division of Cancer, Department of Surgery and Cancer, Imperial College London, SW7 2AZ London, UK, Department of Translational Medicine, Università del Piemonte Orientale "A. Avogadro", 28100 Novara, Italy. Electronic address: david.pinato@imperial.ac.uk
Onesti, Concetta Elisa ; Université de Liège - ULiège > Département des sciences cliniques ; Clinical and Oncological Research Department, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy
De Placido, Pietro; Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy
Harbeck, Nadia; Breast Center, Department OB&GYN and CCCLMU, LMU University Hospital, 81377 Munich, Germany. Electronic address: nadia.harbeck@med.uni-muenchen.de
Lüftner, Diana; Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, 10117 Berlin, Germany. Electronic address: diana.lueftner@charite.de
Denys, Hannelore; Department of Medical Oncology, UZ Gent, 9000 Gent, Belgium. Electronic address: hannelore.denys@ugent.be
Van Dam, Peter; Oncology Department, University Hospital Antwerp (UZA), 2650 Edegem, Belgium. Electronic address: peter.vandam@uza.be
Arpino, Grazia; Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy. Electronic address: grazia.arpino@unina.it
Mustacchi, Giorgio; Medical Oncology, University of Trieste, 34127 Trieste, Italy. Electronic address: mail@mustacchioncology.it
Gligorov, Joseph; Department of Medical Oncology, Tenon Hospital, Institut Universitaire de Cancérologie AP-HP, Sorbonne University, 75004 Paris, France. Electronic address: joseph.gligorov@tnn.aphp.fr
Awada, Ahmad; Oncology Medicine Department, Institut Jules Bordet, Université Libre de Bruxelles, 1000 Bruxelles, Belgium. Electronic address: ahmad.awada@bordet.be
Campone, Mario; Medical Oncology, Institut de Cancérologie de l'Ouest-Pays de la Loire, 44800 Saint-Herblain, France. Electronic address: mario.campone@ico.unicancer.fr
Wildiers, Hans; Department of General Medical Oncology, University Hospital Leuven, 3000 Leuven, Belgium. Electronic address: hans.wildiers@uzleuven.be
Gennari, Alessandra; Department of Translational Medicine, Università del Piemonte Orientale "A. Avogadro", 28100 Novara, Italy. Electronic address: alessandra.gennari@uniupo.it
Tjan-Heijnen, Vivianne; Medical Oncology, Maastricht University Medical Center (MUMC), 6229 HX Maastricht, Netherlands. Electronic address: vcg.tjan.heijnen@mumc.nl
Bartsch, Rupert; Division of Oncology, Department of Medicine 1, Medical University of Vienna, 1090 Vienna, Austria. Electronic address: rupert.bartsch@meduniwien.ac.at
Cortes, Javier; International Breast Cancer Center (IBCC), Quironsalud Group, Barcelona, Spain, Medica Scientia Innovation Research (MedSIR), Barcelona, Spain, Medica Scientia Innovation Research (MedSIR), Ridgewood, NJ, USA, Vall d́Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain, Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain. Electronic address: jacortes@vhio.net
Paris, Ida; Department of Woman and Child Health and Public Health, Woman Health Area, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy. Electronic address: ida.paris@policlinicogemelli.it
Martín, Miguel; Departamento de Medicina, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, 28007 Madrid, Spain. Electronic address: mmartin@geicam.org
De Placido, Sabino; Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy. Electronic address: deplacid@unina.it
Del Mastro, Lucia; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, 16132 Genova, Italy, Department of Medical Oncology, U.O.C Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy. Electronic address: lucia.delmastro@hsanmartino.it
Jerusalem, Guy ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale
Curigliano, Giuseppe; Istituto Europeo di Oncologia, IRCCS ed Università di Milano, 20141 Milano, Italy. Electronic address: giuseppe.curigliano@ieo.it
Prat, Aleix; Translational Genomics and Targeted Therapies in Solid Tumors, 08036 Barcelona, Spain, Department of Medical Oncology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain, Department of Medicine, University of Barcelona, 08036 Barcelona, Spain, Oncology Department, IOB Institute of Oncology, Quiron Group, 08023 Barcelona, Spain, SOLTI Cooperative Research Group, 08008 Barcelona, Spain. Electronic address: alprat@clinic.cat
Generali, Daniele; Department of Medicine, Surgery and Health Sciences, University of Trieste, 34127 Trieste, Italy, Multidisciplinary Unit of Breast Pathology and Translational Research, Cremona Hospital, 26100 Cremona, Italy. Electronic address: dgenerali@units.it
UNITS - Università degli Studi di Trieste FBBVA - Fundación BBVA ESMO - European Society for Medical Oncology
Funding text :
Dr F. Schettini is the recipient of an ESMO Fellowship – Translational and a BBVA Foundation – Hospital Clinic of Barcelona Joan Rodes – Josep Baselga Advanced Research Contract in Oncology. However, any views, opinions, findings, conclusions or recommendations expressed in this material are those solely of the authors and do not necessarily reflect those of Funders. This study was supported by MEDNotE, spin-off - University of Trieste, within the Mozart Program.
Tutt, A., Tovey, H., Cheang, M.C.U., Kernaghan, S., Kilburn, L., Gazinska, P., et al. A randomised phase III trial of carboplatin compared with docetaxel in BRCA1/2 mutated and pre-specified triple negative breast cancer “BRCAness” subgroups: the TNT Trial. Nat Med 24 (2018), 628–637, 10.1038/s41591-018-0009-7.
Gong, Y., Liu, Y.-R., Ji, P., Hu, X., Shao, Z.-M., Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study. Sci Rep, 7, 2017, 45411, 10.1038/srep45411.
Hartman, A.-R., Kaldate, R.R., Sailer, L.M., Painter, L., Grier, C.E., Endsley, R.R., et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer 118:11 (2012), 2787–2795.
Litton, J.K., Rugo, H.S., Ettl, J., Hurvitz, S.A., Gonçalves, A., Lee, K.-H., et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med 379:8 (2018), 753–763.
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S.M., Masuda, N., et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med 377:6 (2017), 523–533.
Cortes, J., Cescon, D.W., Rugo, H.S., Nowecki, Z., Im, S.-A., Yusof, M.M., et al. KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. JCO, 38(15_suppl), 2020, 1000.
Schmid, P., Adams, S., Rugo, H.S., Schneeweiss, A., Barrios, C.H., Iwata, H., et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 379:22 (2018), 2108–2121.
Rozenblit, M., Huang, R., Danziger, N., Hegde, P., Alexander, B., Ramkissoon, S., et al. Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers. J Immunother Cancer, 8(2), 2020, e001558.
Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2014;2:361–70. https://doi.org/10.1158/2326-6066.CIR-13-0127.
National Comprehensive Cancer Network. NCCN Guidelines for Breast Cancer, vers.4.2022 n.d. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (accessed June 28, 2022).
Gennari, A., André, F., Barrios, C.H., Cortés, J., de Azambuja, E., DeMichele, A., et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 32:12 (2021), 1475–1495.
Bardia, A., Mayer, I.A., Vahdat, L.T., Tolaney, S.M., Isakoff, S.J., Diamond, J.R., et al. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med 380:8 (2019), 741–751.
Bardia, A., Hurvitz, S.A., Tolaney, S.M., Loirat, D., Punie, K., Oliveira, M., et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med 384:16 (2021), 1529–1541.
Schettini, F., Chic, N., Brasó-Maristany, F., Paré, L., Pascual, T., Conte, B., et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. npj Breast Cancer, 7(1), 2021, 10.1038/s41523-020-00208-2.
Modi, S., Jacot, W., Yamashita, T., Sohn, J., Vidal, M., Tokunaga, E., et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med 387:1 (2022), 9–20.
Egger SJ, Chan MMK, Luo Q, Wilcken N. Platinum-containing regimens for triple-negative metastatic breast cancer. Cochrane Database Syst Rev 2020;10:CD013750. https://doi.org/10.1002/14651858.CD013750.
Moy, B., Rumble, R.B., Come, S.E., Davidson, N.E., Di Leo, A., Gralow, J.R., et al. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Update. JCO 39:35 (2021), 3938–3958.
Jansen, J.P., Fleurence, R., Devine, B., Itzler, R., Barrett, A., Hawkins, N., et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 14:4 (2011), 417–428.
Hoaglin, D.C., Hawkins, N., Jansen, J.P., Scott, D.A., Itzler, R., Cappelleri, J.C., et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 14:4 (2011), 429–437.
Giuliano, M., Schettini, F., Rognoni, C., Milani, M., Jerusalem, G., Bachelot, T., et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncol 20:10 (2019), 1360–1369.
Li, L., Pan, Z., Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials. Clin Breast Cancer 18 (2018), 63–70, 10.1016/j.clbc.2017.07.015.
Generali, D., Venturini, S., Rognoni, C., Ciani, O., Pusztai, L., Loi, S., et al. A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer. Breast Cancer Res Treat 152:1 (2015), 95–117.
Diéras, Véronique, Han, H.S., Kaufman, B., Wildiers, H., Friedlander, M., Ayoub, J.-P., et al. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21:10 (2020), 1269–1282.
Miles, D., Gligorov, J., André, F., Cameron, D., Schneeweiss, A., Barrios, C., et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol 32:8 (2021), 994–1004.
Cortes, J., Cescon, D.W., Rugo, H.S., Nowecki, Z., Im, S.-A., Yusof, M.M., et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. The Lancet 396:10265 (2020), 1817–1828.
Winer, E.P., Lipatov, O., Im, S.-A., Goncalves, A., Muñoz-Couselo, E., Lee, K.S., et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol 22:4 (2021), 499–511.
Kim, S.-B., Dent, R., Im, S.-A., Espié, M., Blau, S., Tan, A.R., et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 18:10 (2017), 1360–1372.
Dent R, Kim S-B, Oliveira M, Barrios C, O'Shaughnessy J, Isakoff SJ, et al. Abstract GS3-04: Double-blind placebo (PBO)-controlled randomized phase III trial evaluating first-line ipatasertib (IPAT) combined with paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC): primary results from IPATunity130 Cohort A. Cancer Res 2021;81:GS3-04. https://doi.org/10.1158/1538-7445.SABCS20-GS3-04.
Schmid, P., Abraham, J., Chan, S., Wheatley, D., Brunt, A.M., Nemsadze, G., et al. Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. J Clin Oncol 38:5 (2020), 423–433.
Harbeck, N., Saupe, S., Jäger, E., Schmidt, M., Kreienberg, R., Müller, L., et al. A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study. Breast Cancer Res Treat 161:1 (2017), 63–72.
von Minckwitz, G., Puglisi, F., Cortes, J., Vrdoljak, E., Marschner, N., Zielinski, C., et al. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol 15:11 (2014), 1269–1278.
Takashima, T., Mukai, H., Hara, F., Matsubara, N., Saito, T., Takano, T., et al. Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 17:1 (2016), 90–98.
Lunn, D.J., Thomas, A., Best, N., Spiegelhalter, D., WinBUGS - A Bayesian modelling framework: Concepts, structure, and extensibility. Statist Comput 10 (2000), 325–337, 10.1023/A:1008929526011.
Mbuagbaw, L., Rochwerg, B., Jaeschke, R., Heels-Andsell, D., Alhazzani, W., Thabane, L., et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Syst Rev, 6, 2017, 79, 10.1186/s13643-017-0473-z.
Gelman, A., Rubin, D., Inference from iterative simulation using multiple sequences. Statist Sci 7 (1992), 457–511.
Lynch, S.M., Introduction to Applied Bayesian Statistics and Estimation for Social Scientists. Lynch, S.M., (eds.) Introduction to Applied Bayesian Statistics and Estimation for Social Scientists, 2007, Springer New York, New York, NY, 1–7.
Dias S, Ades A, Welton N, Jansen J, Sutton A. Network Meta-Analysis for Decision-Making | Wiley. 1st Edition. John Wiley and Sons; 2018.
Hutton, B., Salanti, G., Caldwell, D.M., Chaimani, A., Schmid, C.H., Cameron, C., et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162:11 (2015), 777–784.
Higgins, J.P.T., Jackson, D., Barrett, J.K., Lu, G., Ades, A.E., White, I.R., Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 3 (2012), 98–110, 10.1002/jrsm.1044.
Dias, S., Welton, N.J., Caldwell, D.M., Ades, A.E., Checking consistency in mixed treatment comparison meta-analysis. Stat Med 29 (2010), 932–944, 10.1002/sim.3767.
R Core Team (2021). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/. n.d.
Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; n.d.
Miles, D., Gligorov, J., André, F., Cameron, D., Schneeweiss, A., Barrios, C., et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol 32:8 (2021), 994–1004.
Delaloge, S., Pérol, D., Courtinard, C., Brain, E., Asselain, B., Bachelot, T., et al. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study. Ann Oncol 27:9 (2016), 1725–1732.
Dieras, V., Pop, S., Berger, F., Dujaric, M.-E., Beuzeboc, P., Escalup, L., et al. First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study. Anticancer Res 37 (2017), 1403–1407, 10.21873/anticanres.11462.
Smith, I.E., Pierga, J.-Y., Biganzoli, L., Cortés-Funes, H., Thomssen, C., Pivot, X., et al. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. Ann Oncol 22:3 (2011), 595–602.
Bramati, A., Girelli, S., Torri, V., Farina, G., Galfrascoli, E., Piva, S., et al. Efficacy of biological agents in metastatic triple-negative breast cancer. Cancer Treat Rev 40:5 (2014), 605–613.
Miles, D.W., Diéras, V., Cortés, J., Duenne, A.-A., Yi, J., O'Shaughnessy, J., First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol 24 (2013), 2773–2780, 10.1093/annonc/mdt276.
Roila, F., Molassiotis, A., Herrstedt, J., Aapro, M., Gralla, R.J., Bruera, E., et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27 (2016), v119–v133.
Klastersky, J., de Naurois, J., Rolston, K., Rapoport, B., Maschmeyer, G., Aapro, M., et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines †. Ann Oncol 27 (2016), v111–v118.
Aapro, M., Beguin, Y., Bokemeyer, C., Dicato, M., Gascón, P., Glaspy, J., et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann Oncol 29 (2018), iv96–iv110.
Schettini, F., Corona, S.P., Giudici, F., Strina, C., Sirico, M., Bernocchi, O., et al. Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial. Front Oncol, 11, 2021, 10.3389/fonc.2021.686776.
Tung, N.M., Robson, M.E., Ventz, S., Santa-Maria, C.A., Nanda, R., Marcom, P.K., et al. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. J Clin Oncol 38:36 (2020), 4274–4282.
Fasching, P.A., Link, T., Hauke, J., Seither, F., Jackisch, C., Klare, P., et al. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Ann Oncol 32:1 (2021), 49–57.
Schettini, F., Giudici, F., Bernocchi, O., Sirico, M., Corona, S.P., Giuliano, M., et al. Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. Eur J Cancer 149 (2021), 134–152.
Tutt, A.N.J., Garber, J.E., Kaufman, B., Viale, G., Fumagalli, D., Rastogi, P., et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med 384:25 (2021), 2394–2405.
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, et al. VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC. Annals of Oncology 2021;0. https://doi.org/10.1016/j.annonc.2021.06.014.
Roche Group Media Relations. Roche provides update on Tecentriq US indication for PD-L1-positive, metastatic triple-negative breast cancer. Roche Media Releases n.d. https://www.roche.com/media/releases/med-cor-2021-08-27.htm (accessed October 18, 2021).
Rugo H, Llombart-Cussac A, Andre F, Robson ME, Saji S, Harbeck N, et al. Abstract OT-30-01: KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or m…. Cancer Research 2021;81:OT-30-01-OT-30-01. https://doi.org/10.1158/1538-7445.SABCS20-OT-30-01.
Garutti, M., Pelizzari, G., Bartoletti, M., Malfatti, M.C., Gerratana, L., Tell, G., et al. Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors. Int J Mol Sci, 20(14), 2019, 3390.
Schmid, P., Cortes, J., Robson, M.E., Iwata, H., Hegg, R., Nechaeva, M., et al. A phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer (CAPItello290). JCO, 38(15_suppl), 2020, TPS1109.
Therapeutics G. G1 Therapeutics Announces Initiation of Phase 3 Registrational Study of COSELATM (trilaciclib) in Triple-Negative Breast Cancer (TNBC). GlobeNewswire News Room 2021. https://www.globenewswire.com/news-release/2021/04/28/2218475/0/en/G1-Therapeutics-Announces-Initiation-of-Phase-3-Registrational-Study-of-COSELA-trilaciclib-in-Triple-Negative-Breast-Cancer-TNBC.html (accessed June 2, 2021).
Schettini, F., Giuliano, M., De Placido, S., Arpino, G., Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives. Cancer Treat Rev 50 (2016), 129–141, 10.1016/j.ctrv.2016.09.004.
Puglisi, F., Rea, D., Kroes, M.A., Pronzato, P., Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review. Cancer Treat Rev 43 (2016), 36–49, 10.1016/j.ctrv.2015.11.012.
Marabelle, A., Le, D.T., Ascierto, P.A., Di Giacomo, A.M., De Jesus-Acosta, A., Delord, J.-P., et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol 38:1 (2020), 1–10.
Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 21:10 (2020), 1353–1365.
Chaimani, A., Higgins, J.P.T., Mavridis, D., Spyridonos, P., Salanti, G., Haibe-Kains, B., Graphical Tools for Network Meta-Analysis in STATA. PLoS ONE, 8(10), 2013, e76654.
Burstein, H.J., Somerfield, M.R., Barton, D.L., Dorris, A., Fallowfield, L.J., Jain, D., et al. Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update. J Clin Oncol 39:35 (2021), 3959–3977.
Bailar, J.C., The promise and problems of meta-analysis. N Engl J Med 337:8 (1997), 559–561.
Greenland, S., Can meta-analysis be salvaged?. Am J Epidemiol 140 (1994), 783–787, 10.1093/oxfordjournals.aje.a117326.
Chaimani A, Caldwell D, Li T, Higgins J, Salanti G. Chapter 11: Undertaking network meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook. n.d.
Dias, S., Sutton, A.J., Ades, A.E., Welton, N.J., Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making 33 (2013), 607–617, 10.1177/0272989X12458724.
Schettini, F., Giuliano, M., Lambertini, M., Bartsch, R., Pinato, D.J., Onesti, C.E., et al. Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. Cancers (Basel), 13(17), 2021, 4421.
